Johnson & Johnson - JNJ STOCK NEWS

On July 15, 2021, Beasley Allen law firm filed a federal class-action lawsuit against Johnson & Johnson (NYSE: JNJ) for selling benzene-tainted sunscreen products from its subsidiaries Neutrogena and Aveeno. The lawsuit seeks damages for consumers who purchased the affected items, which were recalled after lab tests revealed benzene levels exceeding safe limits. Benzene is a hazardous chemical linked to leukemia, raising serious health concerns, especially for children. The FDA prohibits benzene in sun-care products, yet J&J's recall only includes spray products.

Johnson & Johnson Consumer Inc. (NYSE: JNJ) is recalling all lots of five aerosol sunscreen products due to low levels of benzene detected in some samples. This voluntary recall includes NEUTROGENA Beach Defense, Cool Dry Sport, Invisible Daily, Ultra Sheer, and AVEENO Protect + Refresh. Benzene, a human carcinogen, is not an ingredient but was found in finished products. While daily exposure at detected levels is not expected to cause harm, the recall emphasizes consumer safety. Consumers are instructed to stop using these products and contact the Consumer Care Center for refunds.

On July 1, 2021, Johnson & Johnson (NYSE: JNJ) announced strong data supporting its single-shot COVID-19 vaccine's efficacy against the Delta variant, demonstrating persistent immune response lasting at least eight months. The vaccine showed neutralizing antibody activity higher against the Delta variant than previously seen with the Beta variant. The ENSEMBLE trial reported 85% effectiveness against severe illness. The vaccine is available globally on a not-for-profit basis during the pandemic, having received Emergency Use Authorization in the U.S. and Conditional Marketing Authorization in Europe.

Johnson & Johnson (NYSE: JNJ) will conduct a conference call for investors on July 21 at 8:30 a.m. ET to discuss its second-quarter results. Hosted by Joseph J. Wolk, CFO, and Christopher DelOrefice, VP of Investor Relations, the call will also feature Alex Gorsky, CEO. Interested parties can access the call via webcast on the company's website, or by telephone at designated numbers. A replay will be available until August 4. The press release will be issued at 6:45 a.m. ET on the same day.

Johnson & Johnson (NYSE: JNJ) released its 2020 Health for Humanity Report on June 9, 2021, detailing its environmental, social, and governance (ESG) performance. The report highlights progress towards the company's 2020 Goals, its response to COVID-19, and new 2025 Goals, emphasizing health equity and community support. Notable initiatives include a $50 million commitment to health workers and advancements in healthcare access. The report adheres to GRI Standards and includes SASB and TCFD disclosures, showcasing JNJ's dedication to transparency and sustainable value creation.

Johnson & Johnson (NYSE: JNJ) announced a collaboration with the WHO and the government of Sierra Leone to administer its Ebola vaccine regimen as part of an early access clinical program. This initiative aims to prevent further Ebola spread in West Africa, especially following a resurgence of cases in Guinea. The vaccine regimen has received WHO Prequalification, enhancing its accessibility in affected regions. The program targets health workers and vulnerable populations, with plans to vaccinate up to 200,000 individuals. Johnson & Johnson aims to bolster global health preparedness against infectious diseases.

Johnson & Johnson (JNJ) announced the resumption of its COVID-19 single-shot vaccine for adults in the U.S. under Emergency Use Authorization (EUA) following CDC and FDA approval. This decision comes after evaluating a rare blood clotting risk. The vaccine demonstrated 66.1% effectiveness against moderate to severe disease in the Phase 3 ENSEMBLE study. The company plans to file for a Biologics License Application later in 2021. Health authorities continue to monitor safety, emphasizing the need for prompt medical attention for specific symptoms. Updated EUA fact sheets are now available.

Johnson & Johnson (NYSE: JNJ) announced on April 20, 2021, that the European Medicines Agency's Pharmacovigilance Risk Assessment Committee confirmed the positive benefit-risk profile of its COVID-19 vaccine. Following the review of rare adverse events, the company will update vaccine information to include guidance on diagnosing and managing these cases. Shipments of the Janssen COVID-19 vaccine will resume in the EU, Norway, and Iceland. The vaccine demonstrated 85% effectiveness in preventing severe disease during the ENSEMBLE Phase 3 trial, with continued monitoring by health authorities.